Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-47970

ABSTRACT: Cross-species gene expression analysis of species-specific differences in preclinical assessment of pharmaceutical compounds (human)

OTHER RELATED OMICS DATASETS IN: PRJNA208513PRJNA207329PRJNA208509

PROVIDER: E-GEOD-47970 | ExpressionAtlas | 2015-07-15

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-47970-analysis-methods.tsv	Tabular
	E-GEOD-47970-atlasExperimentSummary.Rdata	Rdata
	E-GEOD-47970-configuration.xml	Xml
	E-GEOD-47970-percentile-ranks.tsv	Tabular
	E-GEOD-47970.condensed-sdrf.tsv	Tabular

Items per page:

1 - 5 of 88

Similar Datasets

E-GEOD-47695

Project description:Cross-species gene expression analysis of species-specific differences in preclinical assessment of pharmaceutical compounds (rat)

2015-07-16 | E-GEOD-47695 | ExpressionAtlas

Homo sapiens

Project description:Cross-species gene expression analysis of species-specific differences in preclinical assessment of pharmaceutical compounds (human)

| PRJNA208513 | ENA

Project description:Cross-species gene expression analysis of species-specific differences in preclinical assessment of pharmaceutical compounds

| PRJNA208509 | ENA

Rattus norvegicus

Project description:Cross-species gene expression analysis of species-specific differences in preclinical assessment of pharmaceutical compounds (rat)

| PRJNA207329 | ENA

Cross-species gene expression analysis of species-specific differences in preclinical assessment of pharmaceutical compounds (human)

Project description:Significant qualitative and quantitative differences exist between humans and the animal models used in research. However, significant quantitative and qualitative differences exist between humans and the animal models used in research. This is as a result of genetic variation between human and the laboratory animal. Therefore the development of a system that would allow the assessment of all molecular differences between species after drug exposure would have a significant impact on drug evaluation for toxicity and efficacy. Here we describe a cross-species microarray methodology that identifies and selects orthologous probes after cross-species sequence comparison to develop an orthologous cross-species gene expression analysis tool. The assumptions made by the use of this orthologous gene expression strategy for cross-species extrapolation is that; conserved changes in gene expression equate to conserved pharmacodynamic endpoints. This assumption is supported by the fact that evolution and selection have maintained the structure and function of many biochemical pathways over time, resulting in the conservation of many important processes. We demonstrate this difference using a cross-species methodology by investigating species specific differences of the peroxisome proliferator activator receptor (PPAR) alpha in rat and human.

2014-04-30 | GSE47970 | GEO

Cross-species gene expression analysis of species-specific differences in preclinical assessment of pharmaceutical compounds (rat)

2014-04-30 | GSE47695 | GEO

Cross-species gene expression analysis of species-specific differences in preclinical assessment of pharmaceutical compounds (human)

2014-04-30 | E-GEOD-47970 | biostudies-arrayexpress

Cross-species gene expression analysis of species-specific differences in preclinical assessment of pharmaceutical compounds (rat)

2014-04-30 | E-GEOD-47695 | biostudies-arrayexpress

The effect of red meat consumption on the formation of N-nitroso compounds, a group of compounds which may be harmful to humans, in relation to colorectal cancer

Project description:Study hypothesis: We hypothesise that both colon inflammation and a diet high in red meat increase the endogenous formation of potentially carcinogenic N-nitroso compounds in the human colon and that these compounds increase the colorectal cancer risk, which could (partially) explain the increased colorectal cancer risk that is associated with inflammatory bowel disease and diets high in red meat. Inflammatory bowel disease is characterised by a chronic inflammation within the gastrointestinal tract, which, in case of ulcerative colitis, is present in the colon and rectum. Primary outcome(s): 1. Whole genome gene expression modifications by microarray analysis (4x44K Agilent platform) 2. Apparent total nitroso compounds in faecal matter by thermal energy analysis 3. Faecal water genotoxicity (30 minute exposure to 10% faecal water) by comet assay analysis in the adenocarcinoma cell line Caco-2 All outcomes are measured at baseline and post intervention.

| 2415737 | ecrin-mdr-crc

Cross species differential gene expression

Project description:Cross species differential gene expression

| PRJNA146911 | ENA